You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Meet David

Dramatisation of the impact of a HIV diagnosis and starting treatment with Triumeq

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg. [1]

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.[1]

Based on pooled data from Phase IIb and Phase III clinical studies, the most frequently reported adverse reactions considered possibly or probably related to dolutegravir and abacavir/lamivudine were; Nausea (12%), Insomnia (7%), Dizziness (6%) and Headache (6%).[1]

To learn more about Triumeq, please visit

Triumeq

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies.